Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02443571 · ClinicalTrials.gov registry record
Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)
A clinical trial of Prostatic Neoplasms, sponsored by Blue Earth Diagnostics.
- Completed
- Registry status
- 714
- Enrollment target
- 4
- Study locations
NCT02443571: Completed study of Prostatic Neoplasms, sponsored by Blue Earth Diagnostics.
NCT02443571 is a study of Prostatic Neoplasms that has completed, run by Blue Earth Diagnostics. The registered enrollment target is 714 participants, above the 503-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (42% higher). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02443571, a study of Prostatic Neoplasms, has completed, sponsored by Blue Earth Diagnostics.
- COMPLETED
- Registry status
- 714 participants
- Enrollment target
- 4
- Study locations
Study Summary
This retrospective observational multi centered study has been established to collect the clinical experience relating to the administration of Fluciclovine 18F employed in both investigator initiated studies and named patient/compassionate use programmes in up to 5 sites.
Primary Outcome
Treatment-emergent Adverse Events and Treatment-Emergent Serious Adverse Events
Conditions Studied
Interventions
- RADIATION Fluciclovine (18F)
Study Locations (4)
Other
- University Hospital Sant'Orsola Malpighi - Bologna
- Oslo University Hospital - Oslo
- Aleris Kreftsenter - Oslo
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-06 |
What the finished NCT02443571 record still lists
NCT02443571 is an observational study that tracks outcomes without assigning an intervention. The registered 714 participants enrollment target is mid-sized for trials with a published cap, above the 503-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (42% higher).
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Fluciclovine (18F) is the first listed.
NCT02443571 reports a single indexed study location in Other, Georgia.
Frequently Asked Questions
What is clinical trial NCT02443571 about?
NCT02443571 is a clinical study titled "Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)". This retrospective observational multi centered study has been established to collect the clinical experience relating to the administration of Fluciclovine 18F employed in both investigator initiated studies and named patient/compassionate use programmes in up to 5 sites.
What is the current status of trial NCT02443571?
This trial is currently completed. The enrollment target is 714 participants. The study started on 2015-01. Estimated completion is 2015-06.
What conditions does trial NCT02443571 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT02443571?
The interventions under investigation include: Fluciclovine (18F) (RADIATION).
Who is sponsoring clinical trial NCT02443571?
This trial is sponsored by Blue Earth Diagnostics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02443571 being conducted?
This trial has 4 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02443571's enrollment target sits among peer trials
714 23rd of 65 higher than 43 of 65 other Prostatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prostate Active Surveillance Study
RECRUITING
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
RECRUITING · NA
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
RECRUITING
-
Men at High Genetic Risk for Prostate Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NCT06758401 · 714 participants · Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- NCT04680000 · 716 participants · NA
Chronic Pain Management In Primary Care Using Behavioral Health Consultants
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia